975-P: Nocturnal Glucose Profile According to Predinner Insulin Injection Timing and Prandial and Basal Insulin Types in Type 1 Diabetes People Using Multiple Daily Injections—An Insulclock Connected Insulin Cap–Based Real-World Study

• DOI: 10.2337/db24-975-p
• Publication Date: 2024-06-14T05:22:13Z
• Authors: FERNANDO GOMEZ-PE...; XOÁN VALLEDOR; CRISTINA ABREU; ELSA FERNÁNDEZ-RUBIO; PEDRO PUJANTE ALA...; SHARONA AZRIEL; ROSA CORCOY; LUIS RUIZ-VALDEPEÑAS
• Keywords: Basal (medicine); Insulin degludec

Introduction & Objective: To analyze the influence of timing and type predinner rapid insulin basal on nocturnal glucose profile. Methods: Real-world, retrospective study in T1D people using multiple daily injections. Ten hours from dinner paired continuous monitoring data injections automatically tracked with connected cap Insulclock® were analyzed. Meal events identified ROC detection methodology. Glucometrics evaluated according to injection time around short- long-acting analog types. Results: Nocturnal profiles (n=775, 49 subjects) Higher AUC over 180 mg/dL was observed delayed (mean <u>+</u>SD; x h): -45-15 min (n=136; 17.5%), 175.96 ±271.0; -15-0 (n= 231; 29.8%), 164.0 ±237.1; 0+45 408; 52.6%), 203.6 ±260.9, (p 0.049). Ultrarapid (FiAsp®) vs analogs use associated fewer <70 mg/dl (7.1 13.6; p 0.0051) TBR70 (1.67 4.58%; 0.0036). Events adjusted by baseline similar (glargine U300 degludec). Conclusion: The prandial affect entire Disclosure F. Gomez-Peralta: Advisory Panel; Abbott. Speaker's Bureau; Eli Lilly Company. Insulcloud S.L. Medtronic. Novo Nordisk. Sanofi. X. Valledor: Research Support; C. Abreu: None. E. Fernández-Rubio: Company, Medtronic, Nordisk, Novalab. P. Pujante Alarcón: Dexcom, Inc., AstraZeneca, S. Azriel: A. Menarini Diagnostics, Abbott, Boehringer-Ingelheim, Diabetes, Novartis Pharmaceuticals Corporation, Nordisk Foundation, R. Corcoy: Other Relationship; Sanofi, Roche Diabetes Care, Abbott Menarini. Ypsomed AG. L. Ruiz-Valdepeñas: